# Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy

> **NCT03192826** · PHASE4 · COMPLETED · sponsor: **University Hospital of Patras** · enrollment: 79 (actual)

## Conditions studied

- Posterior Capsule Opacification
- Ocular Hypertension

## Interventions

- **DRUG:** Brinzolamide/Brimonidine FC
- **DRUG:** Brimonidine 0.2%
- **DRUG:** Artificial tears

## Key facts

- **NCT ID:** NCT03192826
- **Lead sponsor:** University Hospital of Patras
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-20
- **Primary completion:** 2017-07-08
- **Final completion:** 2017-07-08
- **Target enrollment:** 79 (ACTUAL)
- **Last updated:** 2019-07-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03192826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03192826, "Brinzolamide/Brimonidine Combination vs Brimonidine 0.2% in the Prevention of IOP Rise After Nd-YAG Laser Capsulotomy". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03192826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*